I think its very possible that they may not end up doing
I think its very possible that they may not end up doing any IPO's in the subsidiaries or if they do, then maybe just one of them. I think this is a back-up plan if they are not able to put together any partnerships. An IPO probably wont occur for another year, so plenty can happen between now and then. They needed to present a plan to the toxics in order for them to agree to the tender exchange, so this is the plan they presented.
Now that the toxics have been removed, they can negotiate much easier with potential partners. Plus they needed to have a plan in place to give them leverage in their negotiations. If a partner sees the company has no options and need the partner to do a trial, they will try to steal the asset, so the Company needs to show them that they don't need the partner to do a trial.
If they can bring on a partner for ESS or Lympro, which I think are the 2 most likely assets to partner in the near term, then hopefully the share price rises to a level which allows a lot of options and doing an IPO may not even be necessary.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
NVIDIA's Conference Call for Third-Quarter Financial Results NVIDIA is preparing to host a conference call where the company's financial results for the third quarter will be addressed. This call is scheduled for Wednesday, November 20, at 2 p.m. PT, allowing both analysts and investors an opportunity to understand the company's performance in a detailed manner. Live...
Continue Reading
Endeavour Mining Conducts Share Buyback Endeavour Mining plc, a leading gold producer, has recently undertaken a strategic initiative by purchasing its own shares in the market. This move signifies a strong commitment to enhancing shareholder value and reflects the company’s robust financial posture. Overview of the Shares Purchased The company acquired a total of...
Continue Reading
Unveiling the Train of Glamour Experience Journey Beyond the Ordinary: The Train is The Destination Welcome aboard the Train of Glamour, a luxurious travel experience that redefines railway tourism in China. With an expanded route schedule in 2025, the Train of Glamour offers travelers a unique opportunity to explore breathtaking Chinese landscapes and diverse cultures....
Continue Reading
Critical Information for Flywire Corporation Investors If you have invested in Flywire Corporation (NASDAQ: FLYW) and experienced financial losses, it’s essential to pay attention to the upcoming deadline for a class action lawsuit. The Law Offices of Frank R. Cruz is reaching out to inform you of your rights regarding your investment losses and the ongoing litigation...
Continue Reading
Innovating in Biotechnology: A Bright Future Ahead The biotechnology sector is witnessing a remarkable transformation, largely fueled by advancements in artificial intelligence (AI). Companies are now leveraging machine learning to effectively identify drug targets, enhance molecular structures, and make accurate predictions regarding clinical trial outcomes. This...
Continue Reading